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Summary The expression of the protease cathepsin-D has been evaluated using an immunohistochemical
technique with a polyclonal antibody in paraffin-embedded tissue from 359 patients treated between the years
1975-1981 for Stage I and II breast cancer. One hundred and twenty seven patients (35%) have strongly
positive, granular staining, 138 (38%) are intermediately stained in the cytoplasm, and in 94 (26%) no staining
is observed. There is a strong positive association between expression of cathepsin-D and the presence of
tumour in axillary lymph nodes (P <0.006). Expression of the protease is associated with significantly poorer
survival of patients in univariate analysis (P = 0.025); however, this is not independent of other tumour
variables.
A significant feature of current research in breast cancer has
been the contribution of biological factors in determining
prognosis in groups of patients. Amongst the factors which
have been the subject of such attention recently is the pro-
tease cathepsin-D (Spyratos et al., 1989; Tandon et al., 1990).
This protease was originally identified as a protein secreted
by oestrogen receptor-expressing cell lines after they were
stimulated with oestrogen (Westley & Rochefort, 1979;
Morisset et al., 1986). Several forms of this protease exist,
these include a precursor, procathepsin-D with a molecular
weight of 52 kilodaltons (Kd). The procathepsin-D is digested
proteolytically in lysosomes to a 48 Kd form and a more
stable 34 Kd form (Yonezawa et al., 1988). Biologically the
molecule acts as a protease, active against basement mem-
brane proteins and proteoglycans (Rochefort et al., 1987).
Some studies have suggested that it is mitogenic for
oestrogen-depleted MCF-7 cells (Rochefort et al., 1987);
however, other workers have not been able to confirm this
finding (Stewart, 1991). In addition, cathepsin-D secreted by
MCF-7 cells participates in the mobilisation of extracellular
matrix-bound basic fibroblast growth factor (Briozzo et al.,
1991).
In view of the above observations, a number of studies
have been conducted on tumour homogenates from patients
with breast cancer using a radioimmune assay (RIA) or
Western blotting to determine whether cathepsin-D has any
clinical relevance. These studies have suggested that a high
cytosolic concentration of cathepsin-D is associated with a
poor prognosis in primary breast cancer. Furthermore, the
association of a high cytosolic concentration of cathepsin-D
in patients with a poor prognosis may be independent of
other prognostic factors, thus rendering, it of particular value
in identifying those patients with no detectable spread of the
primary tumour to the axillary lymph nodes, but who have a
poor prognosis (Spyratos et al., 1989; Tandon et al., 1990).
However, studies in which the expression of cathepsin-D has
been assessed in primary breast cancer using immunohisto-
chemical analysis find ostensibly the reverse result, namely
the presence of immunocytochemically detectable cathepsin-
D is associated with a better prognosis in such patients
(Henry et al., 1990; Merkel et al., 1991). These studies were
not conducted on large numbers ofpatients and the period of
follow-up was relatively short.
The disease of breast cancer has a long natural history
(Brinkley & Haybittle, 1975) and it has been demonstrated
that the duration of follow-up may influence the apparent
significance of prognostic factors which are associated with
the death of the patient (Winstanely et al., 1991a). In order
to address this problem with regards to cathepsin-D and
clarify the apparently contradictory findings from earlier
studies, we have evaluated the expression and clinical
significance of cathepsin-D expression in primary breast car-
cinomas using immunohistochemical techniques for a large
group of patients in whom long-term follow-up data is
available (Winstanley et al., 1991b).
Materials and methods
Patients, specimens andserology
Archival formalin-fixed, paraffin-embedded specimens were
obtained for 359 patients, all of whom had presented with
primary, operable breast cancer between the years 1976-1982
in the Merseyside region, as reported previously (Winstanley
et al., 1991b). Treatment was either modified radical mastec-
tomy or simple mastectomy with sampling of axillary lymph
nodes. The mean age ofpatients was 57 years (range 29-92).
The distribution of the variables:tumour size, nodal status
and histological grade is shown in Table I. All the patients
had invasive carcinomas.
The rabbit polyclonal antiserum to cathepsin-D was raised
against mature cathepsin-D which had been purified from
human spleen by the method of Afting and Becker (1981).
Polyacrylamide gel electrophoresis of the protein used for
immunisation gave a single band of 34 Kd. The antiserum
reacted predominantly with a protein of 34 Kd on Western
blots of the total protein extracts of MCF-7 breast cancer
cells, but minor bands of higher molecular weight (52 Kd,
48 Kd) corresponding to the precursor forms were also
identified (Henry et al., 1990).
Immunocytochemistry
Histological sections were cut from the paraffin-embedded
specimens and were incubated with the polyclonal antibody
to cathepsin-D. The primary antibody was localised by the
peroxidase-antiperoxidase (PAP) method, as described
previously, including the blocking of endogenous peroxidase
with methanol/0.05% H202 (v/v) and the non-specific serum-
binding sites with 10% normal swine serum (Winstanley et
al., 1991b). However, after blocking the endogenous peroxi-
dase activity, the histological sections were partially digested
with 0.1% trypsin (w/v) in 0.1% CaC12 (w/v) for 0 min at
37°C (Curran & Gregory, 1977), as described for the use of
the anti-cathepsin-D serum (Henry et al., 1990). The primary
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Table I Distribution of tumour variables, tumour size, nodal status
and histological grade between patients
Tumour variablea Number ofpatients (%)
T, 30 (9%)
T2 241 (71%)
T3 65 (20%)
N- 229 (64%)
N+ 130 (36%)
GI 50 (27%)
G2 78 (43%)
G3 52 (30%)
aAbbreviations: T, tumour size using the normal convention
(Winstanley et al., 1991a); N, involved (+) or uninvolved (-) lymph
nodes; G, histological grade (Winstanley et al., 1991a).
antibody was used at 1/250 for 90 min at room temperature
and a red coloration due to bound peroxidase was developed
with 3-amino-9-ethyl carbazole (Polyscience Ltd, Northamp-
ton, UK). The cellular nuclei were counterstained blue with
Mayers haemalum.
Slides were read independently by two observers using
light microscopy. Histological sections were regarded as
positive if granular cytoplasmic staining were present in
malignant cells, as reported previously (Henry et al., 1990).
Staining was evaluated initially in three groups: strong,
intermediate, and absent, based on whether the staining
occurred in cytoplasmic granules, throughout the cytoplasm
but not concentrated in granules, or was absent altogether. A
minimum of two sections and ten fields per section at
200 x magnification were analysed. Photographs were
recorded on a Reichert Polyvar microscope fitted with a
Wratten 44 blue-green filter (Rudland & Hughes, 1989).
Consistency of immunocytochemical staining between bat-
ches was checked by including in each batch of 20 sections, a
standard histological section from a known positive speci-
men. Sections stained without anti-cathepsin-D serum or
with the primary antibody preincubated with cathepsin-D
showed no positive staining. Increasing the concentration of
primary antibody 5-fold failed to stain any additional sec-
tions.
Statistical analysis
Follow-up data had previously been obtained from the
Merseyside Cancer Registry for the patients used in this
study and this data for patient survival was updated in
January 1990 (Winstanley et al., 1991b). The association of
cathepsin-D with other tumour variables was assessed using a
simple Chi-square test (Altman, 1991). Since quantitation of
oestrogen receptors was available for a number of the
original tumours removed at the time of presentation, the
association of cathepsin-D with both the presence and the
level of oestrogen receptors was investigated. The presence of
oestrogen receptors was set at a level above 5 fmol mg ' of
cytosolic protein (Winstanley et al., 1991a). The significance
of the association between the levels of oestrogen receptor in
fmol mg-' protein and cathepsin-D was evaluated by a
Mann-Whitney U-test (Altman, 1991).
The association of the production of cathepsin-D in breast
cancers with patient survival was evaluated using life tables
constructed from survival data according to the method de-
scribed by Kaplan and Meier, and analysed using a log-rank
sum (Winstanley et al., 1991b). In order to determine wheth-
er the association of patient survival with cathepsin-D was
independent of other prognostic factors shown to be signifi-
cant in univariate analysis, a multivariate analysis of these
factors was carried out using a Cox multiple regression
model (Cox, 1972). Other prognostic factors measured on the
same group of patients included tumour size, nodal status
and the presence of the oncogene c-erbB-2 (Winstanley et al.,
1991b).
Histological grade was included in this analysis, but data
relating to this prognostic factor was available only for a
smaller sub-set of the whole group of patients. Since the
presence of oestrogen receptors has been shown previously to
lack statistical significance in our group of patients, this
factor was also excluded from the Cox multiple regression
analysis (Winstanley et al., 1991a). The degree of correlation
between observers was assessed using the Kappa statistic, a
value of greater than 0.61 was taken to represent a satisfac-
tory level of agreement (Altman, 1991).
Results
Of the 359 breast carcinomas evaluated, 127 (35%) of them
had strong granular, cytoplasmic staining (Figure la,b), 138
(38%) were intermediately stained in their cytoplasm (Figure
Ic) and the remaining 94 (26%) did not stain (Figure ld).
The assessment was made only on the malignant cells; how-
ever, positive staining was also present in normal histiocytes,
macrophages and blood vessel walls (Figure le). Sometimes
atypical elements of benign breast proliferations within the
primary breast carcinoma were also stained for cathepsin-D,
but they were always associated with staining of the car-
cinoma cells (Figure If). The mean period of follow-up of
the patients was 11 years (range 8-16 years), and their
average age was 57 years at the time of presentation. For the
purposes of analysis both strongly stained and intermediately
stained carcinomas were combined into one group of posi-
tively stained tumours.
Interobserver and intratumour variation
There was some variability in the assessment of staining by
the two observers on the same histological section. However,
there was agreement in 90% of the slides; this corresponded
to a Kappa value of 0.85, which represents a high degree of
consistency between observers. In 4% of all the slides
studied, intratumour heterogeneity affected these slides were
regarded as negatively or positively stained. Intratumour
heterogeneity was assessed by comparing the type of staining
allocated when two sections from the same tumour were read
independently.
Association with other tumour variables
The presence of definite staining for cathepsin-D was cross-
tabulated with other tumour variables using a simple Chi-
square test (Table II). These included tumour size, nodal
Table II Association of cathepsin-D expression with other tumour
variables
Cathepsin-D- Cathepsin-D-
Tumour negative", positiveb, Statistical
variable" no (%) no (%) significancec
TI 7 (8) 23 (9)
T2 59 (71) 182 (71) P =0.95
T3 17 (21) 48 (19) J
N- 71 (75) 158 (59) P = 0.006
N+ 23 (25) 107 (41)
GI 17 (37) 33 (24) "
G2 21 (45) 57 (43) P =0.09
G3 8 (18) 44 (33) J
Erb + 20 (26) 73 (26) P-0.2 Erb - 73 (74) 202 (74) P
ER+ 50 (54) 154 (59)
=04 ER- 42 (46) 105 (41) P
aAbbreviations: T, tumour size using the normal convention
(Winstanley et al., 1991a); N, involved (+) or uninvolved (-) lymph
nodes; G, histological grade (Winstanley et al., 1991a); Erb, the
presence (+) or absence (-) of the c-erbB-2 receptor (Winstanley et
al., 1991b); and ER, the presence (+) or absence (-) of the
oestrogen receptor (Winstanley et al., 1991a). bNumber of patients
with tumours either staining (+) or not staining (-) for
cathepsin-D. Parentheses contain the percentage of patients.
cProbability, P from Chi-square test.CATHEPSIN-D IN BREAST CANCER 769
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Figure 1 Immunocytochemical staining of tumours using anti-cathepsin-D. a, Invasive carcinoma showing strong positive staining
for anti-cathepsin-D. Bar = 50 jm, x 220. b, Higher magnification of A showing the granular nature of the cytoplasmic staining.
Bar = 20fLm, x 550. c, Weak, speckled staining for anti-cathepsin-D of invasive carcinoma (arrows) with strong staining of host
cells (arrowheads). Bar = 50 jAm, x 220. d, invasive carcinoma showing no staining for cathepsin-D. Bar = 50iLm, x 220. e, Host
blood vessels stained positively for cathepsin-D. Bar = 50 jim, x 220. f, Area of epithelial hyperplasia in an invasive carcinoma
showing positive staining of atypical elements. Bar = 50JAm, x 180.
status, histological grade, oestrogen receptor status and the
presence of c-erbB-2. The strongest statistical association was
observed between the presence of staining for cathepsin-D
and the involvement of axillary nodes with tumour; 38% of
cathepsin-D positive tumours had tumour in the associated
axillary lymph nodes compared with only 25% of those that
were cathepsin-D negative (P = 0.006). There was a tendency
for more oestrogen-receptor positive carcinomas to be
positive also for cathepsin-D, when compared with the
oestrogen-receptor negative carcinomas. However, this
tendency did not achieve statistical significance (P - 0.4).
Similarly, the presence ofcathepsin-D staining was associated
with poorly differentiated tumours; but, as in the case of
oestrogen receptors, this association did not achieve statis-
tical significance (P = 0.09). The presence ofcathepsin-D was
also not associated in any significance with higher levels of
oestrogen receptors using the Mann-Whitney U-test
(P = 0.5).
Table III Dependence of the prognostic significance of staining for
cathepsin-D on other prognostic factors using Cox multivariate
regression analysis
Prognostic
factora
N
Erb
T2
T3
Cathepsin
Grade
Coeg
(I
O.I
0.1
0.:~
0.1
0.1
Cox multivariate regression analysis"
ficient Standard error Coefficient * SE
P) (SE) (Z-value)c
77 0.20 3.85
135 0.30 0.67
28 0.31 -0.90
136 0.34 0.40
)68 0.12 0.56
114 0.08 1.42
aAbbreviations are as in Table I; N for involved lymph nodes;
Erb, presence of c-erbB-2 receptor; T2 and T3, tumour size;
cathepsin, presence of cathepsin-D, and grade, histological grade.
bThe values ofparameters ofthe Cox multivariate regression analysis
are shown. cOverall Chi-square = 22.65 for 5 degrees of freedom;
P = 0.0004.
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Figure 2 Association of staining for cathepsin-D with overall survival of the patients. The cumulative proportion of surviving
patients as a percentage of the total is shown for each year after presentation for either a, patients with cathepsin-D-negatively
staining (-) or b, cathepsin-D-positively-staining carcinomas (---). 100% for cathepsin-D-negative carcinomas corresponds to
94 patients, and 100% for cathepsin-D-positive carcinomas corresponds to 265 patients. The two curves are significantly different
(Chi-square = 4.98, 1 degree of freedom, P = 0.025).
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Figure 3 Association of staining for cathepsin-D with survival of patients divided into groups by their c-erbB-2 status. The
cumulative proportion of surviving patients as a percentage of the total is shown for each year after presentation for the following:
a, patients with cathepsin-D-negative, c-erbB-2-negative carcinomas (-) (100% = 71 patients); b, patients with cathepsin-D-
positive, c-erbB-2-negative carcinoma (-----) (100% = 199 patients); c, patients with cathepsin-D-positive, c-erbB-2-positive
carcinomas (----) (100% = 56 patients); d, patients with cathepsin-D-negative, c-erbB-2-positive carcinomas ( ) (100% = 20
patients). The cathepsin-D-negative, c-erbB-2-negative a, and cathepsin-D-positive, c-erbB-2-negative b, curves are significantly
different (Chi-square = 9.2, 1 degree of freedom, P = 0.0024); but the cathepsin-D-positive, c-erbB-2-positive c, and cathepsin-D-
negative, c-erbB-2-positive d, curves are not significantly different (Chi-square = 0.27, 1 degree of freedom, P = 0.6). Data for
c-erbB-2 status is available only for 346 out of the 359 patients.
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Association with patient survival
The association of staining for cathepsin-D and the overall
survival of patients is shown in Figure 2. The data show
that the survival of patients with cathepsin-D-positive car-
cinomas was significantly worse than those not staining for
cathepsin-D (P = 0.025). This effect became apparent early
in the study during the first 2 years of patient follow-up, and
persisted throughout the period of follow-up. At the end of
the period of follow-up there was a 20% difference in sur-
vival between the two groups of patients. The median sur-
vival of patients whose tumours did not stain positively for
cathepsin-D was 180 months compared with 147 months for
those staining for this protease.
The association of cathepsin-D with survival in sub-groups
of patients defined by their tumour size, nodal status, histo-
logical grade, oestrogen-receptor status and c-erbB-2 expres-
sion was analysed. In all of these sub-groups of patients
staining for cathepsin-D was associated with poorer survival.
However, the only group in which this observation was of
statistical significance occurred in those patients not expres-
sing the c-erbB-2 receptor (Figure 3). The statistical validity
may, however, have been influenced by the numbers of
patients in the sub-groups analysed.
Multivariate analysis
In order to test whether the prognostic significance of stain-
ing for cathepsin-D was independent of other prognostic
factors, the data for cathepsin-D was included in a Cox
multivariate regression analysis model. In addition to
cathepsin-D staining, this model included corresponding data
for tumour size, nodal status, c-erbB-2 status and histological
grade. Oestrogen receptor status were excluded for the
reasons outlined earlier. Following analysis using this model
and the only factor that emerged as an independent indicator
of prognosis was nodal status (Table III).
Discussion
Of the previously-published studies evaluating the signifi-
cance of cathepsin-D as a prognostic indicator in primary
breast cancer, two have reported that high levels of
cathepsin-D are associated with a poorer prognosis (Tandon
et al., 1990; Spyratos et al., 1989). Both these studies used
homogenised tumour specimens and RIAs or Western blot-
ting. In contrast, two studies based on immunohistochemical
assessment of cathepsin-D expression found the reverse, in
that its presence was associated with better survival of the
patients (Henry et al., 1990; Merkel et al., 1991). The results
from this present study, which has also used immunohisto-
chemistry to assess production of cathepsin-D, support the
findings from the earlier studies based on RIA.
It is not clear why such marked differences in the observed
effect of this prognostic factor should be present between
studies. However, a number of potential problems exist, and
they fall into two classes, those based on detection of
cathepsin-D and those based on patient groups.
In the first class of problems the method used to determine
cathepsin-D in a tumour may be of some relevance. The
quantitative RIA methods employed to determine the levels
of cathepsin-D in two of the previous reports were applied to
whole tissue specimens, so that analysis was carried out on
normal as well as malignant tissue. However, the immuno-
histochemical studies have demonstrated that some cathep-
sin-D may be present in histyiocytes and other nonmalignant
stromal cells. Thus, some tumours with apparently high levels
of cathepsin-D may, in reality, have only small numbers of
malignant cells containing cathepsin-D. In contrast, all the
immunohistochemical studies have regarded as positive only
those carcinomas with positive staining of malignant cells.
Furthermore, it is not clear what quantitative level of
cathepsin-D determined by RIA coresponds to positive
immunocytochemical staining. It is therefore possible that a
tumour classified as strongly positive using RIAs may appear
negative using immunohistochemical techniques. However,
this cannot be the explanation for the differences between our
work and the other immunohiostochemical studies. In addi-
tion, since the same antibody to cathepsin-D was used in all
the immunohistochemical studies, it is unlikely that cross-
recognition of precursor cathepsin-D or other proteins
related to cathepsin-D is the cause of this discrepancy.
The second class of problems concerns the role played by
statistics in studies assessing the association of a tumour
variable with patient survival. In such studies even minor
differences in the composition of the groups can have a
profound effect on the apparent significance of the prognostic
factor. This study is much larger than the previous study
based on immunocytochemical determination of cathepsin-D
by Henry et al. (1990) which contained 94 patients, although
the proportion of node positive patients was similar as is true
of the study by Spyratos et al. (1989). By comparison with
the study reproted by Tandon et al. (1990), the number of
patients studied was similar to that reported here. However,
75% of such patients had tumour in the axillary lymph
nodes, a larger proportion than that reported in other
studies. Certainly, when all studies of cathepsin-D in breast
cancer are compared, there are differences in the numbers of
patients, clinical staging and duration of follow-up. However,
these do not seem to be consistently associated with a parti-
cular pattern of patient survival. The fact that in our study a
large group of patients is required to obtain a statistically
significant result may mean that small fluctuations in data
can alter considerably the significance of the results.
Similarly, in sub-group analysis patient numbers may be too
small to observe a significant effect. The magnitude of both
inter-observer error and intra-tumour heterogeneity in this
study could conceivably result in such a situation.
Early interest in cathepsin-D in breast cancer arose from
its property of being, in part, an oestrogen-responsive gene,
at least in tissue-cultured cells (Westley & May, 1987). For
this reason expression of cathepsin-D may have seemed likely
to be associated with carcinoma containing appreciable levels
of oestrogen receptors. Although this has been of statistical
significance in some studies (Henry et al., 1990; Tandon et
al., 1990), it is not of statistical significance in this study. The
only association of statistical significance in our study was in
patients with axillary lymph node metastases, a feature ob-
served also by other workers (Tandon et al., 1990; Brouillet
et al., 1990). These observations may, in part, explain the
failure of cathepsin-D to be an independent prognostic
indicator in multivariate analysis. This dependent association
of cathepsin-D and involved axillary lymph nodes on patient
survival supports the contention that the underlying pro-
cesses may themselves be dependent. One such example could
be the requirement of cathepsin-D's proteolytic activity for
invasion and spread to the lymph nodes draining the primary
carcinoma.
In summary cathepsin-D appears to be expressed strongly
in 37% and more weakly in 34% of breast carcinomas and
its granular expression, probably localised to lysosomes, is
associated with a poorer prognosis in these patients. How-
ever, this association with poorer prognosis may simply
relate to the fact that these carcinomas are more likely to
have spread to the axillary lymph nodes. In this study
cathepsin-D does not have the predictive power of nodal
status nor does it clearly identify sub-groups of patients with
an otherwise good prognosis. Therefore, although it may be
of interest in terms of tumour biology, its significance a
prognostic indicator in clinical medicine is debatable.
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